Welcome to Maui Derm NP+PA Fall 2017
September 13-16, 2017 • Hilton New Orleans Riverside • New Orleans, LA
The 4th Annual Maui Derm NP+PA Fall 2017 meeting will be held at the Hilton New Orleans Riverside in New Orleans, Louisiana from September 14-16, 2017. The Fall meeting is part of our “On the Road” program that brings Maui Derm NP+PA to inspired locations throughout the U.S.
This four-day meeting will feature a one day “Special Pre-Conference Day” held on September 13, 2017 followed by our three day meeting.
The highly interactive sessions are designed to validate your current practice patterns while updating your skills in a variety of areas. Based on last year’s requests we have added a surgical workshop, dermatopathology session and a connective tissue disorder symposium.
You will learn some alternate ways to handle common problems and emerging methods to tackle those tough cases. Our world-class faculty have geared their presentations toward providing pearls you can put to use your first day back at work! Disease pathogenesis, differential diagnoses, therapeutic mechanisms of action, treatment algorithms and outcome measures are incorporated into case based discussions. Ample time for Q&A has been built into the program.
We encourage you to join us for what promises to be an exceptional educational opportunity and look forward to meeting you in New Orleans, LA.
Overall Learning Objectives
- Review the pathogenesis of various dermatological conditions such as infectious diseases, nail disorders, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, contact dermatitis, atopic dermatitis, eczema, wounds and wound healing, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, and pigmentary disorders such as vitiligo and melasma in order to accurately diagnose and improve upon the management of these conditions in patients
- Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
- Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
- Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in dermatology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF inhibitors, T-cell targeted therapies, anti-IL-12/23 therapies, IL-17 antibodies, PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL 4/13 antibodies, anti B-cell therapies, retinoids, methotrexate, cyclosporine, oral and topical acne and rosacea therapies, oral and topical antibiotics, antifungals, anti-virals, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical skin repigmenting agents, topical antioxidants and peptides, 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, and photodynamic therapy, and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
- Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
- Discuss the importance of clinician/patient communication regarding benefit versus risk, patient satisfaction, and adherence when selecting therapies for patients
University of Cincinnati
The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Advances in Cosmetic and Medical Dermatology.
The University of Cincinnati designates this live activity for a maximum of 31 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
Based upon the evidence-based content delivered at the Maui Derm NP+PA 2013 conference, the educational e-newsletters will cover the various topics delivered from the meeting. These quarterly e-newsletters will be delivered electronically via an “opt-in” process to the dermatology community. The e-newsletters will include key talking points from the presentations, challenging cases including both diagnostic and management issues, embedded videos and podcasts, and downloadable slides. Topics to be included are:
- Pediatric Dermatology
- Cutaneous Oncology & Pigmented Lesions
- Cutaneous Surgery
- Infectious Disease
- New Drugs
- Cutaneous Immunology
- Oral and Genital Lesions
- Aging Skin & Cosmeceuticals
- Connective Tissue Diseases
The Maui Derm NP+PA Therapeutic Forum is an online forum that discusses hot topics and challenging cases and allows for participants to view pictures and videos that accompany the case studies. Faculty will be available to discuss the cases and viewers will have an opportunity to pose challenging questions to the faculty. All topics and case studies will be based upon the evidence-based medicine discussed at the live meeting. Online forums allow us to assess knowledge gaps and practice patterns and provide a means for future needs assessments.
In accordance with the Americans with Disabilities Act, Maui Derm NP+PA seeks to make this conference accessible to all. If you have a disability which might require special accommodations, please contact Maui Derm at 831-595-0710 or email your needs to: firstname.lastname@example.org.